Abstract
The incidence of spinal cord astrocytomas (SCAs) is very low and therefore, management of these tumors are challenging due to this paucity. In this report, a patient with a recurrent SCA was successfully treated with bevacizumab after failing to previous therapies including radiotherapy (RT) and temozolomide (TMZ). Bevacizumab is an angiogenesis inhibitor that is widely used in high grade gliomas and shows promise for SCAs spinal cord astrocytomas but there is limited data about the usage of bevacizumab in SCAs. We herein add an important contribution to the literature by reporting a nearly total response to bevacizumab in a patient with low grade SCA.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Kahramanmaraş Sütçü İmam Üniversitesi Tıp Fakültesi Dergisi
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
